Search results for " Middle"

showing 10 items of 1097 documents

Sex differences in food choices, adherence to dietary recommendations and plasma lipid profile in type 2 diabetes - The TOSCA.IT study

2016

Background and aims: Diabetic women have a more adverse plasma lipid profile than men. Sex differences in dietary habits may play a role, but are little investigated. The study evaluates the quality of diet, adherence to the nutritional recommendations of the Diabetes and Nutrition Study Group and their relation with plasma lipid in men and women with diabetes. Methods and results: We studied 2573 people, aged 50e75, enrolled in the TOSCA.IT study (clinicaltrials.gov; NCT00700856). Plasma lipids were measured centrally. Diet was assessed with a semi-quantitative food frequency questionnaire.Women had a more adverse plasma lipid profile than men.Women consumed significantly more legumes, veg…

MaleTime FactorsHealthy DietEndocrinology Diabetes and MetabolismSaturated fatMedicine (miscellaneous)Type 2 diabetesCardiovascular risk factors; Diabetes; Dietary habits; Men; Nutritional recommendations; Sex differences; Women; Medicine (miscellaneous); Nutrition and Dietetics; Endocrinology Diabetes and Metabolism; Cardiology and Cardiovascular MedicineDiabeteRecommended Dietary AllowancesChoice Behaviorchemistry.chemical_compound0302 clinical medicineEndocrinologyRisk FactorsCardiovascular risk factors; Diabetes; Dietary habits; Men; Nutritional recommendations; Sex differences; Women; Aged; Biomarkers; Diabetes Mellitus Type 2; Female; Food Preferences; Humans; Italy; Lipids; Male; Middle Aged; Nutrition Assessment; Risk Factors; Sex Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Choice Behavior; Feeding Behavior; Healthy Diet; Patient Compliance; Recommended Dietary Allowances; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular MedicineSurveys and QuestionnairesFood choiceMedicine030212 general & internal medicineFood scienceCardiovascular risk factorsNutrition and DieteticsDietary habitsDiabetesMenMiddle AgedLipidsDiabetes and MetabolismTreatment OutcomeItalySaturated fatty acidFemaleDiet HealthyCardiology and Cardiovascular MedicineType 2030209 endocrinology & metabolismAdded sugarDietary habit03 medical and health sciencesFood PreferencesSex FactorsDiabetes mellitusSex differencesDiabetes MellitusHumansWomenAgedCardiovascular risk factors; Diabetes; Dietary habits; Men; Nutritional recommendations; Sex differences; Women; Aged; Biomarkers; Diabetes Mellitus Type 2; Female; Food Preferences; Humans; Italy; Lipids; Male; Middle Aged; Nutrition Assessment; Risk Factors; Sex Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Choice Behavior; Diet Healthy; Feeding Behavior; Patient Compliance; Recommended Dietary AllowancesHealthybusiness.industryUnsaturated fatNutritional recommendationFeeding BehaviorSex differencemedicine.diseaseDietNutrition AssessmentchemistryDiabetes Mellitus Type 2Patient ComplianceNutritional recommendationsGlycated hemoglobinbusinessBiomarkers
researchProduct

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

2016

International audience; BACKGROUND:We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC).METHODS:In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overal…

MaleTime FactorsIntention to Treat Analysimedicine.medical_treatmentMedizinPROGRESSIONKaplan-Meier EstimateLiver transplantationGastroenterologyImmunosuppressive Agent0302 clinical medicineEVEROLIMUSRENAL-CELL CARCINOMARisk FactorsMedicine and Health SciencesClinical endpointAge FactorSirolimuProspective StudiesIMMUNOSUPPRESSIONTOR Serine-Threonine KinaseTOR Serine-Threonine KinasesHazard ratioLiver NeoplasmsAge FactorsImmunosuppressionMiddle AgedCANCER3. Good healthIntention to Treat AnalysisEuropeRAPAMYCIN INHIBITORSTreatment OutcomeTARGETLocalLiver Neoplasm030220 oncology & carcinogenesisCombinationDisease ProgressionSURVIVAL[SDV.IMM]Life Sciences [q-bio]/Immunology030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmedicine.medical_specialtyCanadaCarcinoma HepatocellularTime Factor[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryRisk AssessmentDisease-Free Survival03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansAdult; Age Factors; Aged; Australia; Canada; Carcinoma Hepatocellular; Disease Progression; Disease-Free Survival; Drug Therapy Combination; Europe; Female; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Prospective Studies; Risk Assessment; Risk Factors; Sirolimus; TOR Serine-Threonine Kinases; Time Factors; Treatment Outcome; Young Adult; Liver Transplantation; TransplantationRECURRENCEMETAANALYSISAgedSirolimusTransplantationEverolimusIntention-to-treat analysisbusiness.industryRisk FactorCarcinomaAustraliaHepatocellular3126 Surgery anesthesiology intensive care radiologySurgeryLiver TransplantationTransplantationProspective StudieNeoplasm RecurrenceSirolimusNeoplasm Recurrence Localbusiness
researchProduct

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

2009

International audience; BACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. METHODS: 19,486 patients with inflammatory bowel disease, of whom 11,759 (60.3%) had Crohn's disease and 7727 (39.7%) had ulcerative colitis or unclassified inflammatory bowel disease, were enrolled in a nationwide French cohort by 680 gastroenterologists, who reported details of immunosuppressive therapy during the observation period, cases of cancer, and deaths. The risk of lymphoproliferative disorder was assessed according to thiopurine expos…

MaleTime FactorsMESH : Age DistributionMESH : Prospective StudiesMESH : AgedInflammatory bowel diseaseMESH: Proportional Hazards Models0302 clinical medicineMESH: Lymphoproliferative DisordersCrohn DiseaseRisk FactorsMESH: Risk FactorsMESH : PurinesMESH : FemaleProspective StudiesMESH: IncidenceProspective cohort studyMESH : Immunosuppressive AgentsMESH : Sex DistributionMESH: AgedMESH : Tumor Necrosis Factor-alphaCrohn's diseaseMESH: Middle AgedThiopurine methyltransferasebiologyMESH : Lymphoproliferative DisordersIncidenceMESH: Sex DistributionGeneral MedicineMESH: PurinesMiddle AgedMESH : AdultMESH : Colitis UlcerativeUlcerative colitisMESH : Risk FactorsMESH : Incidence3. Good health030220 oncology & carcinogenesisCohortDrug Therapy CombinationFemale030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFranceMESH: Immunosuppressive AgentsImmunosuppressive AgentsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyMESH : MaleMESH: Colitis UlcerativeLymphoproliferative disordersMESH : Crohn DiseaseMESH: Multivariate Analysis03 medical and health sciencesAge DistributionInternal medicinemedicineHumansMESH : Middle AgedSex DistributionMESH : FranceMESH: Age DistributionAgedProportional Hazards ModelsMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphabusiness.industryMESH : Drug Therapy CombinationMESH: Time FactorsMESH : HumansMESH : Multivariate AnalysisMESH: Adult[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseMESH : Proportional Hazards ModelsLymphoproliferative DisordersMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceMESH: Drug Therapy CombinationPurinesMESH: Tumor Necrosis Factor-alphaMultivariate Analysisbiology.proteinColitis UlcerativebusinessMESH: Female
researchProduct

Incremental predictive value of mean platelet volume/platelet count ratio in in-hospital stroke after acute myocardial infarction.

2017

IF 2.558; International audience; Stroke is a serious complication after acute myocardial infarction (AMI) and is associated with an increased risk of death. Though the pathophysiological mechanisms are not exactly known, increased inflammation and platelet reactivity could play an important role in the occurrence of stroke during AMI. We aimed to investigate the relationship between both mean platelet volume (MPV), a parameter of platelet function, and C-reactive protein (CRP) and the occurrence of in-hospital ischemic stroke (IHS) after AMI. Data were obtained from a French regional survey for AMI that included 5976 patients admitted to an intensive care unit (ICU) between 2001 and 2010. …

MaleTime FactorsMESH : StrokeMyocardial InfarctionMESH : AgedMESH: ComorbidityComorbidityMESH: Hospitalization030204 cardiovascular system & hematologyMESH : Platelet Countlaw.inventionMESH: Proportional Hazards Models0302 clinical medicineMESH: Aged 80 and overRisk FactorslawMESH: Risk FactorsOdds Ratio[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleMyocardial infarctionMESH : BiomarkersStrokeMESH: Blood PlateletsAged 80 and overMESH: AgedEjection fractionMESH: Middle AgedMESH : PrognosisbiologyMESH : Mean Platelet Volume[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineMiddle AgedPrognosisIntensive care unitstrokeMESH : Risk Factors3. Good healthHospitalizationMESH: Myocardial Infarctionrisk factorplateletsMESH : ComorbidityCardiologyMESH : HospitalizationFemaleMean Platelet VolumeMESH : Time FactorsBlood Plateletsmedicine.medical_specialtyMESH : Male[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAcute myocardial infarctionMESH: PrognosisMESH: StrokeC-reactive protein03 medical and health sciencesInternal medicinemedicineHumansMESH : Middle AgedMESH: Platelet Countcardiovascular diseasesRisk factorMean platelet volumeMESH : Aged 80 and overSurvival analysisAgedProportional Hazards ModelsMESH: HumansPlatelet Countbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyC-reactive proteinMESH: Time FactorsMESH : HumansMESH : Blood Plateletsmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Odds RatioMESH: MaleMESH: Mean Platelet Volumebiology.proteinMESH: BiomarkersMESH : Odds RatioMESH : Myocardial InfarctionbusinessMESH: FemaleBiomarkers030217 neurology & neurosurgery
researchProduct

Papillary muscle relocation in conjunction with valve annuloplasty improve repair results in severe ischemic mitral regurgitation

2012

OBJECTIVE: The incidence of recurrent mitral regurgitation (MR) after restrictive annuloplasty (RA) was 5% to 20% in several reports. There are many opinions in favor of adding subvalvular procedures to RA to reduce the tenting forces and improve the repair results. METHODS: From March 2003 to May 2010, 55 patients with severe ischemic MR who had undergone papillary muscle (PPM) relocation in conjunction with mitral annuloplasty in our institutions were enrolled. The patients were matched 1:1 with those who underwent isolated RA using the propensity score. The mean left ventricular ejection fraction was 42% ± 6%. The mean tenting area and coaptation depth was 3.2 ± 0.6 cm(2) and 1.3 ± 0.2 c…

MaleTime FactorsMitral Valve AnnuloplastyLeftMyocardial IschemiaKaplan-Meier EstimateSeverity of Illness IndexVentricular Function LeftPapillary muscle annuloplasty mitral regurgitationPostoperative ComplicationsRisk FactorsMitral valve annuloplastyAged; Chi-Square Distribution; Disease-Free Survival; Female; Hospital Mortality; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Matched-Pair Analysis; Middle Aged; Mitral Valve Insufficiency; Myocardial Ischemia; Papillary Muscles; Postoperative Complications; Propensity Score; Proportional Hazards Models; Risk Assessment; Risk Factors; Secondary Prevention; Severity of Illness Index; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function Left; Mitral Valve AnnuloplastySecondary PreventionClinical endpointVentricular FunctionHospital MortalityMyocardial infarctionEjection fractionIncidence (epidemiology)Mitral Valve InsufficiencyMiddle AgedPapillary MusclesTreatment Outcomemedicine.anatomical_structureItalyCardiologyFemaleCardiology and Cardiovascular MedicinePulmonary and Respiratory Medicinemedicine.medical_specialtyMatched-Pair AnalysisRisk AssessmentDisease-Free SurvivalInternal medicinemedicineHumansPropensity ScorePapillary muscleAgedProportional Hazards ModelsMitral regurgitationChi-Square Distributionbusiness.industryStroke VolumeSettore MED/23 - Chirurgia Cardiacamedicine.diseaseSurgeryLogistic ModelsPropensity score matchingSurgerybusiness
researchProduct

Augmentation of tibial plateau fractures with an injectable bone substitute: CERAMENT™. Three year follow-up from a prospective study

2015

Background: Reduction of tibial plateau fractures and maintain a level of well aligned congruent joint is key to a satisfactory clinical outcome and is important for the return to pre-trauma level of activity. Stable internal fixation support early mobility and weight bearing. The augmentation with bone graft substitute is often required to support the fixation to mantain reduction. For these reasons there has been development of novel bone graft substitutes for trauma applications and in particular synthetic materials based on calcium phosphates and/or apatite combined with calcium sulfates. Injectable bone substitutes can optimize the filling of irregular bone defects. The purpose of this…

MaleTime FactorsPercutaneousKnee Jointmedicine.medical_treatmentDentistryFracture Fixation InternalFracture FixationTibial plateau fracture Surgical treatment Bone graft Ceramic injectable biphasic bone substitute Clinical and radiographic outcomeFracture fixationTibial plateau fractureOrthopedics and Sports MedicineProspective StudiesTomographyFracture HealingSurgical treatmentBone TransplantationMiddle AgedCombined Modality TherapyBiomechanical PhenomenaX-Ray ComputedDrug CombinationsTreatment Outcomemedicine.anatomical_structureSettore MED/03FemaleResearch ArticleAdultmedicine.medical_specialtyBone healingCalcium SulfateInjectionsRheumatologyClinical and radiographic outcomeTibial plateau fracturemedicineBone graftHumansInternal fixationTibiaTibiabusiness.industryRecovery of Functionmedicine.diseaseInternalSurgeryTibial FracturesDurapatiteCeramic injectable biphasic bone substituteIrregular boneBone SubstitutesOrthopedic surgeryAdult; Biomechanical Phenomena; Bone Substitutes; Bone Transplantation; Calcium Sulfate; Combined Modality Therapy; Drug Combinations; Durapatite; Female; Follow-Up Studies; Fracture Fixation Internal; Fracture Healing; Humans; Injections; Knee Joint; Male; Middle Aged; Prospective Studies; Recovery of Function; Tibia; Tibial Fractures; Time Factors; Tomography X-Ray Computed; Treatment OutcomeTomography X-Ray ComputedbusinessFollow-Up StudiesBMC Musculoskeletal Disorders
researchProduct

Toxicological investigations in a fatal and non-fatal accident due to hydrogen sulphide (H2S)poisoning

2019

Hydrogen sulphide (H2S) is one of the most toxic natural gas and represents a not rare cause of fatal events in workplaces. We report here a serious accidental poisoning by hydrogen sulphide inhalation involving six sailors. Three of them died while the other three survived and were transported to the emergency room. No greenish discolouration of the body, that could be a feature of these type of deaths, was observed at autopsy. Given that blood and/or urine H2S detection does not allow to discriminate if it is related to inhalation or to putrefactive processes, the determination of thiosulphate, H2S main metabolite, is decisive. The succession of fatal events reported here can be rebuilt b…

MaleTime FactorsPoison controlAutopsyFatal accidentBrain EdemaUrine01 natural scienceschemistry.chemical_compound0302 clinical medicineThiosulfateHydrogen sulphideMedicineHydrogen SulfideThiosulfateAir PollutantsOccupational accidentInhalationFatal poisoningMiddle AgedPulmonary edemaFatal poisoning; Hydrogen sulphide; Non-fatal poisoning; Occupational accident; Thiosulphate; Administration Inhalation; Adult; Air Pollutants; Brain Edema; Emphysema; Humans; Hydrogen Sulfide; Hyperemia; Italy; Male; Middle Aged; Military Personnel; Pulmonary Edema; Thiosulfates; Time Factors; Accidents OccupationalOccupationalMilitary PersonnelInhalationItalyAir PollutantAnesthesiaAdministrationNon-fatal poisoningHumanAdultTime FactorThiosulphateThiosulfatesHyperemiaPulmonary EdemaHydrogen sulphidePathology and Forensic Medicine03 medical and health sciencesAdministration InhalationHumansAccidents Occupational030216 legal & forensic medicineEmphysemabusiness.industry010401 analytical chemistrymedicine.disease0104 chemical scienceschemistryAccidentsbusinessLaw
researchProduct

Sleep apnea risk in subjects with asthma with or without comorbid rhinitis

2014

BACKGROUND: As many as 80% of patients with asthma suffer from allergic rhinitis (AR), and rhinitis symptoms are associated with sleep complaints The aim of this cross-sectional study was to assess the prevalence of obstructive sleep apnea syndrome risk in patients with asthma and to explore the association between comorbid rhinitis and obstructive sleep apnea syndrome risk. METHODS: Subjects with asthma were recruited by general practitioners during a control visit. Physicians compiled a questionnaire that assessed the presence of AR according to ARIA (Allergic Rhinitis and Its Impact on Asthma) guidelines and factors influencing the risk of obstructive sleep apnea syndrome (gastroesophage…

MaleTime FactorsSettore MED/10 - Malattie dell'Apparato RespiratorioComorbidityCritical Care and Intensive Care MedicineSeverity of Illness IndexRisk FactorsSurveys and QuestionnairesPrevalenceSurveys and QuestionnaireRhinitisriskSleep Apnea ObstructiveMedicine (all)ApneaSleep apneaGeneral MedicineMiddle Agedsleep apneaFemalemedicine.symptomAllergic rhinitis; Asthma; Obstructive sleep apnea syndrome; Risk; Sleep apnea; STOP-BANG; Pulmonary and Respiratory Medicine; Critical Care and Intensive Care MedicineHumanPulmonary and Respiratory MedicineAdultmedicine.medical_specialtyTime Factorobstructive sleep apnea syndromeAllergicInternal medicineSTOP-BANGSeverity of illnessmedicineAllergic rhinitiHumansAsthmaCross-Sectional Studieallergic rhinitisbusiness.industryObstructiveRisk FactorSTOP-BANG; allergic rhinitis; asthma; obstructive sleep apnea syndrome; risk; sleep apneaOdds ratioasthmamedicine.diseaseObesityComorbidityRhinitis Allergicrespiratory tract diseasesObstructive sleep apneaAllergic rhinitis; Asthma; Obstructive sleep apnea syndrome; Risk; Sleep apnea; STOP-BANG; Adult; Asthma; Comorbidity; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Prevalence; Rhinitis Allergic; Risk Factors; Severity of Illness Index; Sleep Apnea Obstructive; Surveys and Questionnaires; Time FactorsCross-Sectional StudiesPhysical therapybusiness
researchProduct

Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow‐up study

2017

Essentials Late sequelae of isolated superficial vein thrombosis (iSVT) have rarely been investigated. We studied 411 consecutive outpatients with acute iSVT with a median follow-up of three years. Male sex and cancer are risk factors for future deep vein thrombosis or pulmonary embolism. Patients without cancer appear to be at a negligible risk for death. SUMMARY Background Studies of long-term thromboembolic complications and death following acute isolated superficial vein thrombosis (iSVT) of the lower extremities are scarce. Objectives To investigate the course of iSVT in the setting of an observational multicenter study. Methods We collected longitudinal data of 411 consecutive outpati…

MaleTime FactorsSuperficial vein thrombosisDeep veinKaplan-Meier Estimate030204 cardiovascular system & hematology0302 clinical medicineRecurrenceRisk FactorsInterquartile rangecohort study; death; major bleeding; superficial vein thrombosis; venous thromboembolism; Adult; Aged; Anticoagulants; Cause of Death; Female; Hemorrhage; Humans; Incidence; Italy; Kaplan-Meier Estimate; Longitudinal Studies; Lower Extremity; Male; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Proportional Hazards Models; Pulmonary Embolism; Recurrence; Retrospective Studies; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Venous ThrombosisCause of DeathNeoplasmssuperficial vein thrombosiOdds RatioLongitudinal StudiesCause of deathVenous ThrombosisIncidenceAnticoagulantHematologyMiddle AgedThrombosisPulmonary embolismVenous thrombosisTreatment Outcomemedicine.anatomical_structureItalyLower Extremity030220 oncology & carcinogenesisFemaleAdultmedicine.medical_specialtymedicine.drug_classvenous thromboembolismHemorrhage03 medical and health sciencesSex FactorsdeathInternal medicinesuperficial vein thrombosiscohort studymedicineHumansAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryAnticoagulantsmedicine.diseaseSurgerymajor bleedingMultivariate AnalysisPulmonary Embolismbusinesscohort study; death; major bleeding; superficial vein thrombosis; venous thromboembolism; HematologyJournal of Thrombosis and Haemostasis
researchProduct

Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir

2019

Background and Aims: Tenofovir disoproxil fumarate (TDF) is recommended for chronic hepatitis B (CHB) treatment, but it may induce kidney dysfunction whose management is not yet known. This Italian, multicentre, retrospective study aimed to assess the efficacy and safety of switching to entecavir (ETV) patients who developed TDF-associated glomerular and/or tubular dysfunction. Methods: A total of 103 TDF-treated patients were included as follows: age 64 years, 83% male, 49% cirrhotics, 98% with undetectable HBV DNA, 47% with previous lamivudine resistance (LMV-R) and 71% previously treated with adefovir. Twenty-nine (28%) were switched to ETV because estimated glomerular filtration rate (e…

MaleTime FactorsSustained Virologic Responsehepatitis B viruKidneyGastroenterologyhepatitis B virus; liver; liver function tests; renal dysfunction; viral hepatitischemistry.chemical_compound0302 clinical medicine80 and overAdefovirChronicAged 80 and overKidneymedicine.diagnostic_testDrug Substitutionhepatitis B virus; liver; liver function tests; renal dysfunction; viral hepatitis; HepatologyEntecavirMiddle AgedHepatitis BHepatitis BTreatment Outcomemedicine.anatomical_structureItaly030220 oncology & carcinogenesisFemaleKidney Diseases030211 gastroenterology & hepatologyViral hepatitismedicine.drugAdultmedicine.medical_specialtyGuaninehepatitis B virus; liver; liver function tests; renal dysfunction; viral hepatitis; Adult; Aged; Aged 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B Chronic; Humans; Italy; Kidney; Kidney Diseases; Male; Middle Aged; Recovery of Function; Retrospective Studies; Sustained Virologic Response; Tenofovir; Time Factors; Treatment Outcome; Drug Substitutionviral hepatitisRenal functionliverAntiviral Agents03 medical and health sciencesHepatitis B ChronicInternal medicinerenal dysfunctionmedicineHumansliver function testTenofovirAgedRetrospective StudiesCreatinineHepatologybusiness.industryviral hepatitiRecovery of Functionmedicine.diseasechemistryliver function testsbusinessLiver function testshepatitis B virus
researchProduct